Gubra A/S (CPH:GUBRA)

Market Cap	6.16B +7.0%
Revenue (ttm)	2.64B +892.2%
Net Income	1.69B
EPS	102.70
Shares Out	16.33M
PE Ratio	3.67
Forward PE	33.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,775
Open	370.40
Previous Close	371.80
Day's Range	366.40 - 377.80
52-Week Range	293.00 - 557.50
Beta	0.32
Analysts	Buy
Price Target	451.50 (+19.76%)
Earnings Date	Aug 20, 2026

About Gubra

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinfor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 300
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: GUBRA

Analyst Summary

According to 2 analysts, the average rating for GUBRA stock is "Buy." The 12-month stock price target is kr 451.50, which is an increase of 19.76% from the latest price.

Price Target

kr 451.50

(19.76% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 17, 2026

Data Sources Report a data error